BeiGene (BGNE) Reports Q1 Loss of $0.97/Share

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/2/2026

1. INTC
2. AMZN
3. COIN
4. RDDT
5. PINS
6. FSLR
7. SYK
8. DASH
9. MA
10. FND

Go back to BeiGene (BGNE) Reports Q1 Loss of $0.97/Share

BeiGene Reports First Quarter 2016 Financial Results

May 11, 2016 4:15 PM EDT

WALTHAM, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE), a clinical-stage biopharmaceutical company focused on developing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today reported business highlights and financial results for the first quarter of 2016.

We continue to make progress with our four clinical programs, commented John V. Oyler, Chief Executive Officer of BeiGene. In addition to our recent update on BGB-283, a RAF dimer inhibitor, and upcoming data on BGB-A317, an anti-PD-1 antibody, we expect to provide clinical updates on each of our assets this year. ... More